

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Stimulation of the four isoforms of receptor tyrosine kinase ErbB4, but not ErbB1, confers cardiomyocyte hypertrophy**

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1792134> since 2021-08-25T17:42:49Z

*Published version:*

DOI:10.1002/jcp.30487

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the submitted version of the following article: "Stimulation of the four isoforms of receptor tyrosine kinase ErbB4, but not ErbB1, confers cardiomyocyte hypertrophy" which has been published in final form at

1 <https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcp.30487>. This article may be used for non-commercial purposes in accordance  
2 with the Wiley Self-Archiving Policy [<http://www.wileyauthors.com/self-archiving>]

## 3 4 **Stimulation of the four isoforms of receptor tyrosine kinase ErbB4,** 5 6 **but not ErbB1, confers cardiomyocyte hypertrophy** 7

8  
9 Zhen Wang<sup>1</sup>, Hsiu-Wen Chan<sup>2</sup>, Giovanna Gambarotta<sup>3</sup>, Nicola J Smith<sup>4</sup>, Brooke W

10  
11 Purdue<sup>1</sup>, David J Pennisi<sup>5</sup>, Enzo R Porrello<sup>6,7</sup>, Shannon L O'Brien<sup>1</sup>, Melissa E

12  
13 Reichelt<sup>1</sup>, Walter G Thomas<sup>1,#</sup>, Tamara M Paravicini<sup>1,8</sup>  
14

15  
16 *<sup>1</sup> School of Biomedical Sciences; <sup>2</sup> School of Public Health, The University of  
17 Queensland, Brisbane, 4072, Australia; <sup>3</sup> Department of Clinical and Biological  
18 Sciences, University of Torino, Orbassano (Torino), 10043, Italy; <sup>4</sup> School of Medical  
19 Sciences, The University of New South Wales Faculty of Medicine, Sydney, 2052,  
20 Australia; <sup>5</sup> Queensland University of Technology, Brisbane, 4000, Australia; <sup>6</sup>  
21 Murdoch Children's Research Institute, Melbourne, 3052, Australia; <sup>7</sup> Department of  
22 Physiology, School of Biomedical Sciences, The University of Melbourne,  
23 Melbourne, 3010, Australia; <sup>8</sup> School of Health and Biomedical Sciences, RMIT  
24 University, Melbourne, 3083, Australia.*  
25  
26  
27  
28  
29

### 30 **# corresponding author:**

31 Professor Walter G Thomas,  
32 School of Biomedical Sciences,  
33 The University of Queensland  
34 St Lucia, Brisbane 4072, Australia.  
35 Tel: +61 7 33651074; Email: [w.thomas@uq.edu.au](mailto:w.thomas@uq.edu.au)  
36  
37  
38

39 **Running head:** ErbB4 and cardiomyocyte hypertrophy  
40

### 41 **Keywords:**

- 42 • **Hypertrophy**
  - 43 • **Epidermal growth factor receptors**
  - 44 • **Ventricular remodeling**
  - 45 • **Cardiomyocytes.**
- 46  
47  
48

49 Word count of manuscript: 6772 words; 6 Figures  
50  
51

### 52 **Source(s) of funding:**

53 Contract grant sponsor National Health and Medical Research Council of Australia;  
54 Contract grant numbers 1024726 and 1085996 to W.G.T. funded this work.  
55  
56  
57  
58  
59  
60

**Abstract**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Epidermal growth factor (EGF) receptors (ErbB1-ErbB4) promote cardiac development and growth, although the specific EGF ligands and receptor isoforms involved in growth/repair versus pathology remain undefined. We challenged ventricular cardiomyocytes with EGF-like ligands and observed that selective activation of ErbB4 (the receptor for neuregulin 1, NRG1), but not ErbB1 (the receptor for EGF, EGFR), stimulated hypertrophy. This lack of direct ErbB1-mediated hypertrophy occurred despite robust activation of extracellular-regulated kinase 1/2 (ERK) and Akt. Hypertrophic responses to NRG1 were unaffected by the tyrosine kinase inhibitor (AG1478) at concentrations that are selective for ErbB1 over ErbB4. NRG1-induced cardiomyocyte enlargement was suppressed by siRNA knockdown of ErbB4 and ErbB2, whereas ERK phosphorylation was only suppressed by ErbB4 siRNA. Four ErbB4 isoforms exist (JM-a/JM-b and CYT-1/CYT-2), generated by alternative splicing, and their expression declines postnatally and following cardiac hypertrophy. Silencing of all four isoforms in cardiomyocytes, using an ErbB4 siRNA, abrogated NRG1-induced hypertrophic promoter/reporter activity, which was rescued by co-expression of knockdown-resistant versions of the ErbB4 isoforms. Thus, ErbB4 confers cardiomyocyte hypertrophy to NRG1, and all four ErbB4 isoforms possess the capacity to mediate this effect.

## Introduction

Pathological cardiac hypertrophy is an independent risk factor for heart failure and sudden death, and is characterized by the enlargement of individual cardiomyocytes, remodeling of the actin cytoskeleton, and upregulation of hypertrophic genes (Frey and Olson, 2003; Marian and Braunwald, 2017).

Cardiomyocyte hypertrophy can be induced by local factors, such as neuregulin 1 (NRG1, a member of the epidermal growth factor ligand family) (Zhao et al., 1998), as well as a variety of physiological (e.g. pregnancy or exercise training) and pathological stimuli including hypertension and the vasoactive peptide, angiotensin II (AngII) (Brandt et al., 2012; Eghbali et al., 2005; Pelliccia et al., 1991; Sadoshima and Izumo, 1993). Apart from NRG1, 14 other EGF-like ligands exist (Wilson et al., 2009), although their contribution to cardiac function is less clear.

The epidermal growth factor receptors (ErbBs) are a family of tyrosine kinase receptors that regulate cell growth, survival and differentiation (Burgess, 2008). Upon activation by EGF ligands, ErbB receptors form hetero- or homo-dimers and phosphorylate intracellular tyrosine residues to activate downstream signaling pathways. They have four subtypes (ErbB1 - 4) (Burgess, 2008). ErbB1 (also known as the Epidermal Growth Factor Receptor, EGFR), ErbB2 and ErbB4 are abundant in postnatal cardiomyocytes and are essential for cardiac development and normal function in the adult heart (D'Uva et al., 2015; Gassmann et al., 1995; Lee et al., 1995; Reichelt et al., 2017; Threadgill et al., 1995; Vermeulen et al., 2016; Wadugu and Kuhn, 2012), ErbB2, which cannot bind ligands, is the preferred dimerization partner for ErbB1 and ErbB4 (Burgess, 2008).

1  
2  
3 The ErbB4 selective agonist NRG1 is produced by vascular endothelial cells and  
4  
5 activates ErbB4 on cardiomyocytes in a paracrine manner to regulate cardiac  
6  
7 physiology (Parodi and Kuhn, 2014). *In vitro*, NRG1 induces robust cardiomyocyte  
8  
9 hypertrophy, presumably via ErbB4 (Baliga et al., 1999; Zhao et al., 1998). ErbB4  
10  
11 has four main isoforms due to alternative splicing: JM-a CYT-1, JM-a CYT-2, JM-b  
12  
13 CYT-1 and JM-b CYT-2 (Veikkolainen et al., 2011). These four isoforms are  
14  
15 structurally different in two domains, the juxtamembrane (JM) domain and the  
16  
17 cytoplasmic (CYT) domain; The JM-a, but not JM-b, isoform allows shedding of the  
18  
19 ectodomain by metalloproteases (Veikkolainen et al., 2011), whereas the CYT-1  
20  
21 isoform has an additional 16 amino acids, which allows binding with PI3K  
22  
23 (phosphoinositide 3-kinase) (Veikkolainen et al., 2011) and ubiquitin ligases.  
24  
25  
26 (Sundvall et al., 2008) The four isoforms of ErbB4 have profound differences in their  
27  
28 function in many tissues; for example, the JM-a isoforms are capable of suppressing  
29  
30 astrocyte differentiation, whereas the JM-b isoforms are not (Sardi et al., 2006). The  
31  
32 function of different isoforms in cardiomyocytes remains uninvestigated.  
33  
34  
35  
36  
37  
38  
39

40 In this study, we evaluated the influence of growth receptor ligands on  
41  
42 cardiomyocyte hypertrophy, and used loss- and gain-of-function strategies to  
43  
44 investigate the role of the four ErbB isoforms in mediating the hypertrophic response.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Materials and methods

### *Animals*

All experiments were conducted in accordance with the Australian Code of Practice for Care and Use of Animals for Scientific Purposes and approved by the institutional ethics committees of the University of Queensland. RNA was isolated from CD-1 mouse hearts at embryonic days 10.5, 13.5, 16.5, and 18.5, and postnatal days 1, 6, 14 and 28. RNA was also obtained from adult mice with cardiac-specific overexpression of the calcium-dependent phosphatase calcineurin. These mice develop cardiac hypertrophy soon after birth and reached maximal hypertrophy at 8 weeks of age, progressing to dilated cardiomyopathy and heart failure (Molkentin et al., 1998).

### *Myocyte culture*

Neonatal rat ventricular myocytes (NRVM) were isolated from ventricles of 1-2 day old Sprague Dawley rats and purified via gradient centrifugation as previously described (Thomas et al., 2002). To mimic the up-regulation of AT<sub>1</sub>R during hypertrophy, AT<sub>1</sub>R was delivered into cardiomyocytes with DNA transfection or adenovirus (Thomas et al., 2002) as required and indicated in the figures. Cardiomyocytes were stimulated with the following hypertrophic agents at concentrations as indicated in graphs: AngII, NRG1 (NRG1-β1), EGF, amphiregulin, betacellulin, transforming growth factor α, epiregulin, epigen, HB-EGF, neuregulins - 1α, -1β1, -2α, -2β, -3 and -4. To induce the activation of ERK, promoter activity of hypertrophic genes and hypertrophic growth (increase of protein to DNA ratio), cardiomyocytes were treated with indicated agonists for 5min, 48h and 48-72h separately. The ErbB receptor antagonist, AG1478, was added to cells 30 min

1  
2  
3 before stimulation at concentrations, as indicated.  
4

#### 5 6 *Hypertrophy assay* 7

8  
9 Cells were lysed in TE buffer containing 0.06% SDS for 4h at room temperature, and  
10  
11 assayed for both protein (BCA assay, Thermo Scientific) and DNA content  
12  
13 (Picogreen dsDNA assay kit, Life Technologies). Before the DNA assay, cell lysates  
14  
15 were treated with 0.2g/L proteinase K (Life Technologies) overnight. Hypertrophy  
16  
17 was defined by the increase in the total protein in the absence of a change in DNA  
18  
19 levels (Thomas et al., 2002).  
20  
21

#### 22 23 *Phalloidin stain* 24

25  
26 Cardiomyocytes were fixed with 4% paraformaldehyde followed by staining with  
27  
28 Alexa594-labelled phalloidin as per the manufacturer's protocol (Invitrogen) and  
29  
30 imaged on a confocal microscope (400x magnification, Olympus FV1000 Inverted  
31  
32 Confocal, Japan) to reflect the F-actin reorganization into the sarcomere.  
33  
34

#### 35 36 *siRNA transfection* 37

38  
39 The day after cardiomyocyte isolation, siRNAs specific for ErbB2 and ErbB4 were  
40  
41 mixed with Lipofectamine® RNAiMAX (Life Technologies) and transfected into cells  
42  
43 at a final concentration of 20nM. Non-targeting siRNA was used as a control. ErbB2  
44  
45 (L-090224-02), ErbB4 (L-080170-02) and non-targeting siRNA (D-001810-10) was  
46  
47 predesigned and purchased from Dharmacon (ON-TARGETplusSMARTpool).  
48  
49 Cardiomyocytes were transfected with siRNA 48h before treatment with agonists.  
50  
51

#### 52 53 *Plasmid constructs* 54

55  
56 The shRNA for ErbB2 and ErbB4 were designed using online BLOCK-iT™ RNAi  
57  
58 Designer program (Invitrogen). To achieve high knockdown rates, the shRNA was  
59  
60

1  
2  
3 engineering into a microRNA 155 backbone by introducing a stem-loop structure.  
4  
5 DNA oligonucleotides corresponding to each shRNA were synthesised and cloned  
6  
7 into BLOCK-iT™ Pol II miR RNAi Expression Vector (Invitrogen) as per  
8  
9 manufacturer's protocols.  
10

### 11 12 13 *Generation of knockdown-resistant ErbB4 constructs*

14  
15 To generate ErbB4 expression constructs that are resistant to knockdown by the  
16  
17 ErbB4 shRNA, a segment common to all four ErbB4 isoforms (residues 1-1455)  
18  
19 encompassing the shRNA targeting site, was excised from the pIRESpuro2 vector  
20  
21 containing the ErbB4 coding region and subcloned into the pSL301 vector via NheI  
22  
23 and HpaI digestion. PCR mutagenesis was performed on the pSL301/ErbB4 (1-  
24  
25 1455) plasmid using the kdrErbB4 primers designed to introduce mutations in the  
26  
27 shRNA target site of ErbB4 (i.e., the kdrErbB4 primer forward  
28  
29  
30

31  
32 5'-CTACATCACGGACAACCTCCAATCTCTGCTACTACCACACCATCAAC;  
33

34  
35 reverse 5'-GTTGATGGTGTGGTAGTAGCAGAGATTGGAGTTGTCCGTGATGTAG).  
36

37  
38 The PCR products were transformed into XL1-blue competent cells and the  
39  
40 introduction of silent mutations was confirmed by sequencing. The common, mutated  
41  
42 segment (1-1455) was subcloned back into the four individual ErbB4 constructs in  
43  
44 pIRESpuro2 via NheI and HpaI digestion and ligation. Positive clones were  
45  
46 determined by sequencing.  
47

### 48 49 *DNA transfection and luciferase reporter assay*

50  
51  
52 Reporter assays were used to measure activation of the prototypic hypertrophic  
53  
54 genes. Luciferase reporter plasmids driven by hypertrophic gene promoter (MLC-2V,  
55  
56 ANP-328, and cyclin D) were gifts from Dr Mona Nemer (University of Ottawa,  
57  
58  
59  
60



1  
2  
3 Canada). Cardiomyocytes, seeded in 12-well plates, were transiently transfected  
4 with 300ng plasmid DNA for the luciferase reporter constructs, along with other DNA  
5 constructs (100ng AT<sub>1</sub>R (Figure 1) and 100ng shRNA targeting specific ErbBs, and  
6 100ng knockdown resistant ErbB4 isoforms (Figure 6) or 20-100ng knockdown  
7 resistant ErbB4 isoforms (Figure 6)) using Lipofectamine™ 2000 (Life Technologies).  
8 The hypertrophic signaling was induced by treatment with AngII, NRG1 or EGF for  
9 48h. The cells were harvested and assayed with a luciferase assay kit (Promega).  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 *Western blot*

21  
22 Western blots of cellular lysates were probed with primary antibodies to  
23 ErbB4 (sc-283, Santa Cruz), ErbB2 (Ab-3, Calbiochem), p-ERK (#9106, Cell  
24 Signalling), ERK(#4695, Cell Signalling) and β-actin (AC-15, Sigma), phospho-Akt-  
25 Ser473 (#9271, Cell Signalling), Akt (#9272, Cell Signalling). IRDye-conjugated  
26 secondary antibodies were used before imaging with LI-COR Odyssey infrared  
27 imaging system (LI-COR biotechnology). LI-COR Image Studio Lite software  
28 (version 3.1) was used to quantify protein expression.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 *Absolute quantification real-time PCR*

40  
41 RNA was extracted from animal tissues or cultured cells using TRIzol reagent  
42 (Invitrogen) and cDNA was synthesized with the SuperScript™III Reverse  
43 Transcriptase Kit (Invitrogen) according to the company's instructions. DNA  
44 containing each ErbB4 isoform was digested from ErbB4 isoform cloning vectors,  
45 purified in gel and serially diluted (1:5) to generate the standards. The concentration  
46 of standard DNA was estimated by measuring the absorbance at 260 nm. Standards  
47 and the unknown samples were amplified in the same plates with Taqman PCR in  
48 following conditions: 300nM of primers (Sigma), 200nM of probe, 1×Taqman  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 advanced fast master mix (Applied Biosystems) and 5-10 ng templates in a 10 $\mu$ l  
4 reaction volume. Cycling was initiated 20s at 95°C, followed by 40 cycles of 1s at  
5 95°C and 20s at 60°C. The probes and primers used for each isoforms are: JM-a  
6 probe [6FAM]ATGGACGGGCCATTCCACTTTACCA[BHQ1],  
7  
8 JM-b probe [6FAM]TTCAAGCATTGAAGACTGCATCGGCCT[BHQ1]; JM-a/JM-b  
9 forward TTGCCATCCAAACTGCACC, JM-a/JM-b reverse  
10  
11 TCCAATGACTCCGGCTGC; CYT-1 probe  
12  
13 [6FAM]TGAAATTGGACACAGCCCTCCTCCTG[BHQ1], CYT-2 probe  
14  
15 [6FAM]AAGAATTGACTCCAATAGGAATCAGTTTGTGTACCA[BHQ1];CYT-1/CYT-2  
16  
17 forward TCCTCCCATCTACACATCCAGAA, CYT-1/CYT-2 reverse  
18  
19 GGCATTCCTTGTGTGTAGCAA. Gene expression data are represented as  
20  
21 absolute copy number of each isoform per ng total RNA.  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 *Statistical analysis*

32  
33 Data are all shown as mean  $\pm$  SEM. Unless specifically indicated, data were  
34 analyzed using a one- or two-way ANOVA with Bonferroni post-hoc comparisons  
35 (Figures 2-4), or were log transformed to achieve equal variance distribution for each  
36 group before analysis via two-way ANOVA with Dunnett's multiple comparison  
37 (Figure 6). Data were considered statistically significant at  $p < 0.05$ .  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### 3.1 Growth receptor ligands and hypertrophy development

We sourced a range of EGF-like ligands that activate primarily ErbB1, ErbB4 or both and tested their capacity to cause hypertrophy in ventricular cardiomyocytes (Figure 1A). The most efficacious hypertrophic agents were betacellulin (BTC; maximal growth  $149 \pm 1\%$  compared to unstimulated), NRG1- $\beta$ 1 ( $134 \pm 2\%$ ), NRG2 $\beta$  ( $134 \pm 2\%$ ). Amphiregulin, TGF $\alpha$ , epireglin, NRG2 $\alpha$  and NRG3 stimulated moderate levels of hypertrophy ( $116 \pm 2$ ,  $118 \pm 3$ ,  $120 \pm 3$ ,  $123 \pm 3$ , and  $124 \pm 3\%$ , respectively). Hypertrophy was weak or absent when induced by EGF, HB-EGF, NRG4, epigen, and NRG1 $\alpha$  ( $107 \pm 2$ ,  $109 \pm 2$ ,  $110 \pm 3$ ,  $113 \pm 2$ ,  $113 \pm 3\%$ , respectively).

Both isoforms of ERK (ERK1/2) and Akt are downstream targets of hypertrophic signalling. We therefore tested EGF-like ligands for their capacity to activate these intracellular signaling pathways. Following 5 minutes of ligand stimulation, EGF, TGF $\alpha$ , BTC, epiregulin and NRG1- $\beta$ 1 induced the strongest activation of ERK and Akt (Figure 1B). Amphiregulin, NRG1 $\alpha$ , and epigen also stimulated ERK phosphorylation, but to a lesser degree. Interestingly, while demonstrating equivalent activation of ERK and Akt, ligands were not equivalent in their ability to stimulate hypertrophy.

We next assessed the ability of BTC, NRG1- $\beta$ 1, NRG-2 $\beta$  to promote induction of hypertrophic genes and sarcomeric reorganization (both markers of cardiomyocyte hypertrophy). We examined the capacity for ErbB ligands to promote ANP gene expression using an ANP promoter-driven luciferase reporter construct (Thomas et

1  
2  
3 al., 2002). Cardiomyocytes were transfected with both the luciferase reporter, and  
4 HA-tagged AT<sub>1</sub>R and stimulated with agonists for 48h. NRG1-β1, NRG2β and BTC  
5 induced ANP promoter activity to the same extent as AngII, whereas EGF was  
6  
7  
8  
9  
10 unable to modify promoter activity (Figure 1C).

11  
12  
13  
14  
15 Sarcomeric reorganization was observed via phalloidin staining of actin filaments.  
16  
17 TRITC-labelled phalloidin was used to stain AdNHA-AT<sub>1</sub>-infected cardiomyocytes  
18 (Thomas et al., 2002) stimulated with 100nM AngII, 10nM EGF, 10nM BTC, 10nM  
19  
20  
21 NRG1-β1 and 10nM NRG2β or left unstimulated for 72h (Figure 1D). AngII-treated  
22  
23  
24 cardiomyocytes developed striated actin filaments, whereas cardiomyocytes  
25  
26  
27 stimulated with EGF resembled unstimulated cells. In contrast, BTC, NRG1-β1 or  
28  
29  
30 NRG2β were able to induce actin reorganization, indicating a capacity to promote  
31  
32  
33 hypertrophy.

34  
35  
36 To complement our observation that EGF-like ligands, capable of activating ErbB4  
37  
38  
39 receptors, are the strongest promoters of hypertrophy, we used AG1478 to  
40  
41  
42 pharmacologically inhibit ErbB activity, and evaluated phosphorylation of ERK  
43 (Figure 2A) and ANP promoter activity (Figure 2B). At higher concentrations of  
44  
45  
46 AG1478 (5μM), but not 0.5μM, both ERK phosphorylation and ANP promoter activity  
47  
48  
49 induced by NRG1-β1 were blocked. Consistent with previous reports that at 0.5μM  
50  
51  
52 AG1478 selectively inhibits ErbB1 receptors, whereas at 5μM AG1478 inhibits both  
53  
54  
55 ErbB1 and ErbB4 receptors (Anastassiadis et al., 2011), our data indicate a selective  
56  
57  
58  
59  
60 role for ErbB4 in NRG1-mediated hypertrophy.

### 3.2. *ErbB4* is required for *NRG1-β1*-induced hypertrophic signaling

Because our data mitigated against a role for direct, ligand-induced ErbB1-mediated hypertrophy, we next developed shRNA constructs that specifically knockdown ErbB2 and ErbB4 (supplementary Figure S1, A and B) and determined the effect of this knockdown on *NRG1*-stimulated hypertrophic gene expression, using MLC-2v, cyclin D and ANP promoter-driven luciferase reporter constructs. *NRG1*-induced MLC-2v, cyclin D and ANP promoter activity was significantly inhibited with knockdown of ErbB4 (Figure 2 C-E). As a corollary to our promoter-reporter assays, where only a small proportion of the myocytes were transfected with reporter and shRNA plasmid DNA (Djurovic et al., 2004; Louch et al., 2011), we also developed siRNAs that targeted ErbB2/ErbB4, because these siRNAs provide a higher knockdown efficiency in cardiomyocytes. Knockdown of ErbB2 (Figure S2, left) and ErbB4 (Figure S2, right) was observed for up to 96h after transfection. This knockdown was selective for the targeted subtype, as knockdown of ErbB2 did not affect expression of ErbB4 and vice versa (supplementary Figure S2).

*NRG1-β1* stimulation increased ERK phosphorylation in cardiomyocytes (Figure 3 A and B). siRNA mediated knockdown of ErbB4 reduced *NRG1-β1*-induced phosphorylation of ERK by ~40% relative to the siControl (Figure 3A and B). In contrast, silencing of ErbB2 did not affect *NRG1-β1*-induced hypertrophic signaling (Figure 3A and B). This indicates that ErbB4 is the primary mediator of *NRG1-β1*-induced ERK signaling in cardiomyocytes.

We next sought to confirm that *NRG1-β1* acts via the ErbB4 receptor to cause cardiomyocyte hypertrophy, as distinct from signaling activation. *NRG1-β1*-induced

1  
2  
3 hypertrophic growth was significantly reduced (~ 50% compared to siControl) by  
4  
5 down-regulation of ErbB4 and ErbB2 (Figure 3C). Consistent with this, NRG1- $\beta$ 1  
6  
7 induced sarcomere reorganization was also affected by knockdown of ErbB4 and  
8  
9 ErbB2 (Figure 3D).  
10  
11  
12  
13

### 14 *3.3. Expression profiles of ErbB4 isoforms during physiological and* 15 16 *pathophysiological cardiac hypertrophy*

17  
18 ErbB4 has four isoforms that differ structurally in the juxtamembrane (JM) domain  
19  
20 (JM-a and JM-b) and the intracellular CYT domain (CYT-1 and CYT-2, Figure 4A).  
21  
22 Expression of all ErbB4 isoforms were highest prenatally and significantly decreased  
23  
24 after birth (supplementary Figure S3), with the ratio of JM-b to JM-a increasing  
25  
26 postnatally. Figure 4B compares expression of ErbB4 in rat ventricular  
27  
28 cardiomyocytes isolated from P1 neonates, to that expressed in whole mouse hearts  
29  
30 at P1 and P28. We identify dominant expression of the JM-b isoform over JM-a, and  
31  
32 comparable expression of the CYT-1 and CYT-2 isoforms (Figure 4B).  
33  
34  
35  
36  
37  
38  
39

40 A transgenic model of cardiac hypertrophy caused by calcineurin overexpression  
41  
42 (Molkentin et al., 1998) was used to investigate the regulation of ErbB4 isoforms in  
43  
44 pathological hypertrophy. Expression of all of four isoforms was significantly reduced  
45  
46 (except JM-a,  $p=0.09$ ) in calcineurin-overexpressing animals compared to the  
47  
48 controls (Figure 4C). The JM-b:JM-a and CYT-2:CYT-1 ratios were unchanged,  
49  
50 suggesting that the reduction of all isoforms reflects a global change in ErbB4 gene  
51  
52 expression and not the specific splicing of individual isoforms.  
53  
54  
55  
56  
57

### 58 *3.4. The role of ErbB4 isoforms in NRG1- $\beta$ 1-induced cardiomyocyte hypertrophy*

1  
2  
3 To examine individual contributions of ErbB4 isoforms to NRG1- $\beta$ 1-induced  
4 cardiomyocyte hypertrophy, we inhibited endogenous ErbB4 expression using  
5 selective shRNA constructs (as detailed above) and used knockdown-resistant  
6 versions of the ErbB4 isoforms to rescue the expression of individual isoforms. Silent  
7 mutations were introduced into the ErbB4 isoforms to make them “knockdown-  
8 resistant” (kdr) to the ErbB4 shRNA (Figure 5A), and we confirmed that protein  
9 expression of kdrErbB4 receptors was not inhibited by ErbB4 shRNA 1386 (Figure  
10 5B).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Knockdown of ErbB4 markedly reduced NRG1- $\beta$ 1-induced MLC-2V, ANP and cyclin  
25 D promoter activity (Figure 6 A-C). Hypertrophic responses were rescued by all four  
26 kdr-ErbB4 isoforms, indicating that the NRG1- $\beta$ 1 induced cardiomyocyte hypertrophy  
27 must be dependent on a common feature shared by all the isoforms (e.g. tyrosine  
28 kinase activity). One possible confounder in interpreting these data was our  
29 observation that expression of the kdr-ErbB4 isoforms led to an increase in both  
30 basal and NRG1- $\beta$ 1 stimulated promoter-reporter activity, suggesting that supra-  
31 physiological expression of ErbB4 receptor isoforms with constitutive activity might  
32 increase basal signalling. We were concerned that this overexpression could be  
33 masking an isoform-specific preference for NRG1- $\beta$ 1-mediated hypertrophy and  
34 therefore performed titration experiments with varying amounts of the kdr-ErbB4  
35 isoforms (Figure 6D). These experiments show that no clear preference for one  
36 isoform of ErbB4 exists in relation to the NRG1- $\beta$ 1-mediated hypertrophic gene  
37 program.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

The receptors belonging to the ErbB family play an important role in the heart: abundant in cardiomyocytes, they coordinate cardiac development, physiology and growth in response to local and circulating factors, including NRG1- $\beta$ 1 (Parodi and Kuhn, 2014). We evaluated the capacity of ligands for ErbB receptors to induce cardiomyocyte hypertrophy, identifying a principal role for ligands that activate ErbB4, and surprisingly, a minimal role for ligands that directly activate ErbB1. NRG1- $\beta$ 1-induced hypertrophy was dependent on ErbB4, and may also involve ErbB2. All four ErbB4 receptor isoforms (JM-a, JM-b, CYT-1 and CYT-2) exist in heart, with the JM-b isoform predominant in terms of expression. We observed a decrease in the expression of the ErbB4 isoforms postnatally, and also in a genetic model of pathological cardiac hypertrophy (Molkentin et al., 1998). Finally, we used an RNA interference/rescue experiment to demonstrate that all four ErbB4 isoforms possess the capacity to mediate NRG1- $\beta$ 1 stimulated cardiomyocyte hypertrophic signaling, indicating that a common feature of ErbB4 isoforms (likely their tyrosine kinase activity) is the determinant of this function.

Our observation of potent hypertrophic effects of NRG1- $\beta$ 1 confirms previous reports in neonatal myocytes (Baliga et al., 1999), and studies showing NRG1- $\beta$ 1 improves cardiac function and prognosis for ischaemic, dilated and viral cardiomyopathy (Giraud et al., 2005; Liu et al., 2006; Rohrbach et al., 1999). Other members of the NRG family – NRG2 $\alpha$ , NRG2 $\beta$  and NRG3 – also strongly stimulated hypertrophy, particularly NRG2 $\beta$ . The NRGs also interact with ErbB3, however, the low expression of this subtype in the adult heart (Sundaresan et al., 1998; Zhao et al.,



1  
2  
3 1998) makes it unlikely that this receptor is mediating hypertrophy. The strongest  
4 hypertrophic agonist of all the EGF-like growth factors was BTC, which interacts with  
5 both ErbB1 and ErbB4, while also inducing heterodimerisation of these receptors  
6 with ErbB2 (Roskoski, 2014). Given that the strongest inducers of hypertrophy were  
7 BTC, NRG1- $\beta$ 1, and NRG2 $\beta$ , which all have high affinity interactions with ErbB4, the  
8 data strongly suggest that this ErbB subtype must be a critical mediator of neonatal  
9 cardiomyocyte growth.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 The inability of HB-EGF or EGF, both ErbB1 ligands, to stimulate hypertrophy  
22 directly is interesting. These findings contrast studies by Asakura *et al.* (Asakura *et*  
23 *al.*, 2002) who document a >2-fold increase in [ $^3$ H] Leucine incorporation following  
24 HB-EGF stimulation. They also contrast with the conclusions of Yoshioka *et al.* who  
25 report a 25% increase in cell size and 34% increase in [ $^3$ H] Leucine incorporation  
26 with adenoviral-directed HB-EGF overexpression (Yoshioka *et al.*, 2005). We were  
27 unable to demonstrate a direct role for HB-EGF (via ErbB1) with our hypertrophy  
28 assays (protein:DNA ratio, ANP promoter activity and cellular reorganization) up to  
29 100  $\mu$ M, despite being able to detect robust hypertrophy induction via multiple  
30 hypertrophy agents, including AngII, BTC, NRG1- $\beta$ 1 and NRG2 $\beta$  with all assays. We  
31 also observed no or little hypertrophy with other ErbB1 agonists, including EGF,  
32 amphiregulin, hTGF $\alpha$ , and epiregulin. Together, these data indicate that direct  
33 activation of EGFR (ErbB1), and very strong activation of growth signaling pathways  
34 (e.g., ERK and Akt), is not apparently sufficient to drive hypertrophy. An uncoupling  
35 of ERK/Akt activation and hypertrophy induction is consistent with previous  
36 publications by us (Kaakinen *et al.*, 2017) and others (Kehat and Molkentin, 2010).  
37 There is also an apparent disconnect between the lack of ErbB1-mediated  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 hypertrophy by direct stimulation by its ligands (e.g., EGF and HB-EGF) and the  
4  
5 plethora of literature implicating ErbB1 in the growth of cells in response to  
6  
7 “transactivation” by GPCRs, (Forrester et al., 2016) indicating that ErbB1 activation  
8  
9 is necessary, but not sufficient in itself, for hypertrophy emanating from GPCRs.  
10  
11

12  
13  
14 ErbB2 is important in many aspects of cardiac physiology (D'Uva et al., 2015;  
15  
16 Vermeulen et al., 2016). Interestingly, ErbB2 lacks a ligand-binding domain and thus  
17  
18 acts in response to EGF-like factors via dimerization with other ErbB receptors and it  
19  
20 is a preferential partner for ErbB4 (Roskoski, 2014; Wilson et al., 2009). In our  
21  
22 studies, specific downregulation of ErbB2 using RNAi did not affect NRG1- $\beta$ 1-  
23  
24 induced activation of ERK. However, NRG1- $\beta$ 1-induced increases in protein to DNA  
25  
26 ratio and actin reorganization were attenuated by the knockdown of ErbB2,  
27  
28 comparable to that seen with ErbB4 knockdown. Thus, it appears ErbB2 contributes  
29  
30 to NRG1- $\beta$ 1-stimulated cardiomyocyte hypertrophy.  
31  
32  
33

34  
35  
36  
37 After identifying ErbB4 as a primary mediator of growth factor-induced  
38  
39 cardiomyocyte hypertrophy, the focus of our study was then to evaluate the relative  
40  
41 expression of ErbB4 isoforms in heart and their contribution to hypertrophy. These  
42  
43 isoforms differ in their ability to be cleaved (JM-a isoforms) or not (JM-b isoforms),  
44  
45 and to release an intracellular domain that can interact with multiple cellular factors  
46  
47 and trigger specific signaling pathways (Ni et al., 2001; Veikkolainen et al., 2011).  
48  
49 Furthermore, isoforms containing the CYT-1 domain have extra amino acids that  
50  
51 interact with additional factors (e.g. YAP, STAT5, PI3K), whereas the CYT-2 domain  
52  
53 lacks this binding site (Omerovic et al., 2004; Sundvall et al., 2008; Veikkolainen et  
54  
55 al., 2011; Williams et al., 2004). This can lead to potentially profound functional  
56  
57  
58  
59  
60

1  
2  
3 differences between isoforms, as observed in the context of mammary development,  
4 astrogenesis, cancer and cell survival (Junttila et al., 2000; Muraoka-Cook et al.,  
5 2009; Sardi et al., 2006; Sundvall et al., 2010).  
6  
7  
8  
9

10  
11  
12 We observed that both the JM-a and JM-b isoforms are detectable in the adult  
13 mouse heart, although the JM-b isoform is predominant. The expression of CYT1  
14 and CYT2 was comparable. Our observation that JM-b is the major isoform in adult  
15 heart is consistent with previous studies (Elenius et al., 1999; Elenius et al., 1997;  
16 Veikkolainen et al., 2011), although some failed to detect expression of JM-a,  
17 presumably due to limits in the sensitivity of their assays (traditional end-point PCR  
18 versus qPCR in ours). We observed that ErbB4 is expressed at a much higher level  
19 in the embryonic heart than in the adult (Figure S3). The high level of ErbB4 in  
20 embryonic heart is consistent with the strong requirement for cardiac growth during  
21 embryonic (Gassmann et al., 1995) and postnatal stages (Garcia-Rivello et al., 2005).  
22 We also characterized the cardiac expression of ErbB4 isoforms in an *in vivo* model  
23 of pathological hypertrophy with overexpression of calcineurin (Molkentin et al.,  
24 1998). All four isoforms were reduced significantly, with no selective regulation  
25 between isoforms. The decrease in ErbB4 with pathological hypertrophy is  
26 consistent with that observed for ErbB4 (and ErbB2) in failing human hearts  
27 (Rohrbach et al., 2005). One interpretation of this decrease is that ErbB4  
28 suppression is a compensation to an over-driven hypertrophy or perhaps related to  
29 pathology, perhaps by driving proapoptotic pathways (Rohrbach et al., 2005).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 To investigate the specific role of ErbB4 isoforms in hypertrophy, we developed a  
57 'rescue' strategy using shRNA to knockdown endogenous ErbB4 isoforms, in  
58  
59  
60

1  
2  
3 conjunction with expression of knockdown-resistant (kdr) versions of individual  
4 isoforms. NRG1- $\beta$ 1 mediated MLC2V, ANP and Cyclin D promoter activation was  
5 abrogated by knockdown of ErbB4 and expression of each kdr ErbB4 isoform was  
6 sufficient to rescue promoter activity. In these experiments, we noted constitutive  
7 and enhanced levels of hypertrophic signaling, likely due to the supraphysiological  
8 levels of the kdr isoforms. Therefore, we titrated the amount of the knockdown-  
9 resistant constructs to see if the lower expression levels exposed selective  
10 differences in their capacity to mediate hypertrophy. No statistically significant,  
11 isoform-specific differences were observed, consistent with a common feature of  
12 ErbB4 isoforms (most likely the tyrosine kinase activity) being responsible for the  
13 ability of these receptors to mediate hypertrophic growth. It will be interesting in  
14 future experiments to use kinase-deficient mutants to confirm this assumption. A lack  
15 of an isoform-specific effect was surprising given the dominance of the JM-b isoform  
16 and the differential role of ErbB4 isoforms in other tissues (Määttä et al., 2006;  
17 Muraoka-Cook et al., 2009; Sardi et al., 2006; Sundvall et al., 2010; Zhu et al., 2006).  
18 Our data show that all ErbB4 isoforms can sustain cardiomyocyte hypertrophy, but  
19 future studies should focus on the role of ErbB4 isoforms in proliferation and  
20 regeneration. (Polizzotti et al., 2015; Vermeulen et al., 2016; Wadugu and Kuhn,  
21 2012)

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 Despite the well-established role for ErbB1 in mediating transactivation via GPCRs,  
50 such as the AT<sub>1</sub>R (Forrester et al., 2016; George et al., 2013; Thomas et al., 2002),  
51 direct stimulation of ErbB1 by its ligands is insufficient to induce cardiac hypertrophy.  
52 Instead, we identified a critical role for direct ligand stimulation of the ErbB4 receptor  
53 in cardiomyocyte hypertrophy. In contrast to distinct roles for individual ErbB4  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 isoform in other settings, cardiomyocyte hypertrophic signaling can be mediated  
4  
5 equivalently by all ErbB4 isoforms, indicating that ectodomain shedding and CYT-1-  
6  
7 directed signalling of ErbB4 do not contribute to cardiomyocyte hypertrophy.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

**Acknowledgements:**

We thank Dr. Mona Nemer (University of Ottawa) for kindly providing the hypertrophic gene promoter luciferase reporter plasmids (MLC-2V, ANP-328, and cyclin D), Dr Andrew Dunbar (formerly of GroPep Limited, South Australia) for bovine betacellulin, Professor David Riese II (Auburn University) for neuregulin isoforms -2 $\alpha$ , -2 $\beta$ , -3 and -4, and Mr. James Goonan for constructing the shRNA plasmids for ErbB2 and ErbB4. We also gratefully acknowledge cardiac tissue provided by Professor Karen Moritz (University of Queensland).

For Peer Review

## References

- Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. 2011. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. *Nat Biotechnol* 29(11):1039-1045.
- Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. *Nat Med* 8(1):35-40.
- Baliga RR, Pimental DR, Zhao YY, Simmons WW, Marchionni MA, Sawyer DB, Kelly RA. 1999. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. *The American journal of physiology* 277(5 Pt 2):H2026-2037.
- Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. 2012. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. *J Am Coll Cardiol* 59(10):901-909.
- Burgess AW. 2008. EGFR family: structure physiology signalling and therapeutic targets. *Growth Factors* 26(5):263-274.
- D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, Weisinger K, Bassat E, Rajchman D, Yifa O, Lysenko M, Konfino T, Hegesh J, Brenner O, Neeman M, Yarden Y, Leor J, Sarig R, Harvey RP, Tzahor E. 2015. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. *Nat Cell Biol* 17(5):627-638.
- Djurovic S, Iversen N, Jeansson S, Hoover F, Christensen G. 2004. Comparison of nonviral transfection and adeno-associated viral transduction on cardiomyocytes. *Mol Biotechnol* 28(1):21-31.
- Eghbali M, Deva R, Alioua A, Minosyan TY, Ruan H, Wang Y, Toro L, Stefani E. 2005. Molecular and functional signature of heart hypertrophy during pregnancy. *Circ Res* 96(11):1208-1216.

- 1  
2  
3 Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. 1999. Characterization of a naturally  
4 occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase.  
5  
6 Oncogene 18(16):2607-2615.  
7  
8  
9  
10 Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD, Klagsbrun M. 1997. A novel juxtamembrane  
11 domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential  
12 processing in response to phorbol ester. J Biol Chem 272(42):26761-26768.  
13  
14  
15  
16 Forrester SJ, Kawai T, O'Brien S, Thomas W, Harris RC, Eguchi S. 2016. Epidermal Growth Factor  
17 Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the  
18 Cardiovascular System. Annu Rev Pharmacol Toxicol 56:627-653.  
19  
20  
21  
22  
23 Frey N, Olson E. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol  
24 65(1):45-79.  
25  
26  
27  
28 Garcia-Rivello H, Taranda J, Said M, Cabeza-Meckert P, Vila-Petroff M, Scaglione J, Ghio S, Chen J, Lai  
29 C, Laguens RP, Lloyd KC, Hertig CM. 2005. Dilated cardiomyopathy in Erb-b4-deficient  
30 ventricular muscle. Am J Physiol Heart Circ Physiol 289(3):H1153-1160.  
31  
32  
33  
34 Gassmann M, Casagrande F, Orioli D, Simon H, Lai C, Klein R, Lemke G. 1995. Aberrant neural and  
35 cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378(6555):390-  
36 394.  
37  
38  
39  
40  
41 George AJ, Hannan RD, Thomas WG. 2013. Unravelling the molecular complexity of GPCR-mediated  
42 EGFR transactivation using functional genomics approaches. FEBS J 280(21):5258-5268.  
43  
44  
45  
46 Giraud MN, Fluck M, Zuppinger C, Suter TM. 2005. Expressional reprogramming of survival pathways  
47 in rat cardiocytes by neuregulin-1beta. J Appl Physiol (1985) 99(1):313-322.  
48  
49  
50 Junttila TT, Sundvall M, Määttä JA, Elenius K. 2000. ErbB4 and Its Isoforms: Selective Regulation of  
51 Growth Factor Responses by Naturally Occurring Receptor Variants. Trends Cardiovasc Med  
52 10(7):304-310.  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 Kaakinen M, Reichelt ME, Ma Z, Ferguson C, Martel N, Porrello ER, Hudson JE, Thomas WG, Parton  
4  
5 RG, Headrick JP. 2017. Cavin-1 deficiency modifies myocardial and coronary function, stretch  
6  
7 responses and ischaemic tolerance: roles of NOS over-activity. *Basic Res Cardiol* 112(3):24.  
8  
9
- 10 Kehat I, Molkentin JD. 2010. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac  
11  
12 hypertrophy. *Ann N Y Acad Sci* 1188:96-102.  
13
- 14 Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. 1995. Requirement for neuregulin receptor  
15  
16 erbB2 in neural and cardiac development. *Nature* 378(6555):394-398.  
17  
18
- 19 Liu Q, Wilkins BJ, Lee YJ, Ichijo H, Molkentin JD. 2006. Direct interaction and reciprocal regulation  
20  
21 between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth. *Mol Cell Biol*  
22  
23 26(10):3785-3797.  
24
- 25 Louch WE, Sheehan KA, Wolska BM. 2011. Methods in cardiomyocyte isolation, culture, and gene  
26  
27 transfer. *J Mol Cell Cardiol* 51(3):288-298.  
28  
29
- 30 Määttä JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K. 2006. Proteolytic  
31  
32 cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-  
33  
34 independent survival and cancer cell growth. *Mol Biol Cell* 17(1):67-79.  
35  
36
- 37 Marian AJ, Braunwald E. 2017. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical  
38  
39 Manifestations, Diagnosis, and Therapy. *Circ Res* 121(7):749-770.  
40
- 41 Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. 1998. A  
42  
43 calcineurin-dependent transcriptional pathway for cardiac hypertrophy. *Cell* 93(2):215-228.  
44  
45
- 46 Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA,  
47  
48 Earp HS. 2009. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert  
49  
50 opposing effects on the mammary epithelium in vivo. *Mol Cell Biol* 29(18):4935-4948.  
51  
52
- 53 Ni CY, Murphy NP, Golde TE, Carpenter G. 2001. Gamma-secretase cleavage and nuclear localization  
54  
55 of ErbB-4 receptor tyrosine kinase. *Science* 294(5549):2179-2181.  
56  
57  
58  
59  
60

- 1  
2  
3 Omerovic J, Puggioni EMR, Napoletano S, Visco V, Fraioli R, Frati L, Gulino A, Alimandi M. 2004.  
4  
5 Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls  
6  
7 transcription at the nuclear level. *Exp Cell Res* 294(2):469-479.  
8  
9  
10 Parodi EM, Kuhn B. 2014. Signalling between microvascular endothelium and cardiomyocytes  
11  
12 through neuregulin. *Cardiovasc Res* 102(2):194-204.  
13  
14 Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. 1991. The upper limit of physiologic cardiac  
15  
16 hypertrophy in highly trained elite athletes. *N Engl J Med* 324(5):295-301.  
17  
18  
19 Polizzotti BD, Ganapathy B, Walsh S, Choudhury S, Ammanamanchi N, Bennett DG, dos Remedios CG,  
20  
21 Haubner BJ, Penninger JM, Kuhn B. 2015. Neuregulin stimulation of cardiomyocyte  
22  
23 regeneration in mice and human myocardium reveals a therapeutic window. *Sci Transl Med*  
24  
25 7(281):281ra245.  
26  
27  
28 Reichelt ME, O'Brien S, Thomas WG, Headrick JP. 2017. Transactivation of the epidermal growth  
29  
30 factor receptor in responses to myocardial stress and cardioprotection. *Int J Biochem Cell*  
31  
32 *Biol* 83:97-110.  
33  
34  
35 Rohrbach S, Niemann B, Silber RE, Holtz J. 2005. Neuregulin receptors erbB2 and erbB4 in failing  
36  
37 human myocardium -- depressed expression and attenuated activation. *Basic Res Cardiol*  
38  
39 100(3):240-249.  
40  
41  
42 Rohrbach S, Yan X, Weinberg EO, Hasan F, Bartunek J, Marchionni MA, Lorell BH. 1999. Neuregulin in  
43  
44 cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4  
45  
46 receptors. *Circulation* 100(4):407-412.  
47  
48  
49 Roskoski R, Jr. 2014. The ErbB/HER family of protein-tyrosine kinases and cancer. *Pharmacol Res*  
50  
51 79:34-74.  
52  
53  
54 Sadoshima J, Izumo S. 1993. Molecular characterization of angiotensin II--induced hypertrophy of  
55  
56 cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor  
57  
58 subtype. *Circ Res* 73(3):413-423.  
59  
60

- 1  
2  
3 Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G. 2006. Presenilin-dependent ErbB4 nuclear signaling  
4 regulates the timing of astrogenesis in the developing brain. *Cell* 127(1):185-197.  
5  
6  
7 Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP. 1998. Biological response to ErbB  
8 ligands in nontransformed cell lines correlates with a specific pattern of receptor expression.  
9  
10 *Endocrinology* 139(12):4756-4764.  
11  
12  
13 Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM, Aqeilan RI, Elenius K. 2008.  
14 Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced  
15 ErbB4 isoforms. *Proc Natl Acad Sci U S A* 105(11):4162-4167.  
16  
17  
18 Sundvall M, Veikkolainen V, Kurppa K, Salah Z, Tvorogov D, van Zoelen EJ, Aqeilan R, Elenius K. 2010.  
19 Cell Death or Survival Promoted by Alternative Isoforms of ErbB4. *Mol Biol Cell* 21(23):4275-  
20 4286.  
21  
22  
23 Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. 2002. Adenoviral-directed  
24 expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via  
25 transactivation of the epidermal growth factor receptor. *Circ Res* 90(2):135-142.  
26  
27  
28 Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T,  
29 Herrup K, Harris RC, et al. 1995. Targeted disruption of mouse EGF receptor: effect of genetic  
30 background on mutant phenotype. *Science* 269(5221):230-234.  
31  
32  
33 Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M, Elenius K. 2011. Function of ERBB4 is  
34 determined by alternative splicing. *Cell Cycle* 10(16):2647-2657.  
35  
36  
37 Vermeulen Z, Segers VF, De Keulenaer GW. 2016. ErbB2 signaling at the crossing between heart  
38 failure and cancer. *Basic Res Cardiol* 111(6):60.  
39  
40  
41 Wadugu B, Kuhn B. 2012. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special  
42 focus on effects on cardiomyocyte proliferation. *Am J Physiol Heart Circ Physiol*  
43 302(11):H2139-2147.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE. 2004. The  
4  
5 ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A  
6  
7 nuclear chaperone. *J Cell Biol* 167(3):469-478.  
8  
9  
10 Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ, 2nd. 2009. Functional selectivity of EGF family  
11  
12 peptide growth factors: implications for cancer. *Pharmacol Ther* 122(1):1-8.  
13  
14 Yoshioka J, Prince RN, Huang H, Perkins SB, Cruz FU, MacGillivray C, Lauffenburger DA, Lee RT. 2005.  
15  
16 Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted  
17  
18 autocrine/paracrine heparin-binding EGF. *Proc Natl Acad Sci U S A* 102(30):10622-10627.  
19  
20  
21 Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. 1998. Neuregulins promote  
22  
23 survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in  
24  
25 neonatal and adult ventricular myocytes. *J Biol Chem* 273(17):10261-10269.  
26  
27  
28 Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE. 2006.  
29  
30 Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine  
31  
32 signal in breast tumor cells. *Cancer Res* 66(16):7991-7998.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure Legends:****Figure 1: Role of growth factor ligands in cardiac hypertrophy development.**

**A)** Rat neonatal ventricular cardiomyocytes were subjected to a titration of EGF-like ligands for 60-72 hrs. Hypertrophy assays were performed using protein/DNA lysates from cardiomyocyte preparations (n=3-4). **B)** Cardiomyocytes were stimulated with growth receptor ligands (10 nM) for 5 min and ERK and Akt activation were detected by western blot. **C)** Cardiomyocytes were stimulated with the agonists Ang II (100nM), EGF (1nM), NRG1- $\beta$ 1 (1nM), NRG2 $\beta$  (1nM) or BTC (1nM) for 72 h to induce ANP promoter activity, assessed by a luciferase reporter. **D)** The presence of sarcomeric reorganisation was detected by TRITC-labelled phalloidin staining. The white bar in the first panel is 10  $\mu$ m. \* p<0.05 vs. unstimulated.

**Figure 2. Effects of the ErbB inhibitor AG1478 on ERK phosphorylation and hypertrophic gene promoter activity in response to NRG1- $\beta$ 1.**

**A)** Cells were treated with AG1478 (0.5 or 5  $\mu$ M) for 30 min before stimulating with NRG1 (NRG1- $\beta$ 1, 10 nM) for 5 min. Levels of total and phosphorylated ERK were assessed by Western blot; images are representative of two independent experiments. **B)** Cardiomyocytes were transfected with 100 ng shControl and 300 ng ANP promoter-driven luciferase reporter constructs. 24 h later, cells were treated with AG1478 as indicated and stimulated with NRG1 (NRG1- $\beta$ 1, 10 nM) for 48 h. Data are presented as mean  $\pm$  SEM (n=3) of relative light units normalized to the unstimulated control and analysed by two-way ANOVA with Bonferroni post-test (\*P<0.05 vs control (no AG1478) treated with NRG1- $\beta$ 1). **C-E)** Cardiomyocytes were transfected with 100 ng AT<sub>1</sub>R, 100 ng ErbB shRNA or shControl, and 300 ng of either MLC-2V (C), ANP (D)

1  
2  
3 or cyclin D (E) promoter-driven luciferase reporter constructs. 24 h after transfection  
4  
5 cells were stimulated with NRG1 for 48 h. Data are presented normalized to the  
6  
7 NRG1-stimulated, shControl (\* $P < 0.05$  vs NRG-stimulated shControl) (n=3-5).  
8  
9

10  
11  
12 **Figure 3. Selective knockdown of ErbB receptors differentially affects**

13 **hypertrophy induced by NRG1- $\beta$ 1.** Cardiomyocytes were transfected with siErbB2,  
14  
15 siErbB4 or siControl and 48 h later, cells were stimulated with NRG1 (NRG1- $\beta$ 1, 10  
16  
17 nM) for 5 min. **A)** Representative western blot images showing ERK activation; **B)**  
18  
19 Quantification of pERK/total ERK in NRG1 (NRG1- $\beta$ 1, 10 nM) stimulated cells (n=4).  
20  
21 **C)** Protein:DNA ratio was determined following NRG1 (NRG1- $\beta$ 1, 10 nM, 48 h)  
22  
23 stimulation and data normalized to the unstimulated, siControl (left) and **D)**  
24  
25 Cardiomyocytes were fixed and stained with phalloidin following stimulation with  
26  
27 NRG1 (NRG1- $\beta$ 1, 10 nM, 48 h). Bar = 10  $\mu$ m. \* $p < 0.05$  vs siControl, n=5), ‡,  $p < 0.05$   
28  
29 vs unstimulated.  
30  
31  
32  
33  
34  
35  
36  
37

38 **Figure 4. ErbB4 isoform expression in cardiac tissues** **A)** The four isoforms of  
39  
40 ErbB4 structurally differ in two domains: the extracellular juxtamembrane (JM)  
41  
42 domain (JM-a and JM-b) and intracellular CYT domain (CYT-1 and CYT-2). The JM-  
43  
44 a isoform contains 23 amino acids that allow for ectodomain shedding, while JM-b  
45  
46 contains an alternative 13 amino acids resistant to shedding. CYT-1 is a 16 amino  
47  
48 acid protein docking site. **B)** Absolute quantitative qPCR (TaqMan) of ErbB4  
49  
50 isoforms in neonatal rat ventricular cardiomyocytes and in whole hearts isolated  
51  
52 from neonatal P1 and P28 hearts and **C)** Absolute quantitative qPCR of ErbB4  
53  
54 isoforms in hearts from 8 week old transgenic mice with hypertrophy due to cardiac-  
55  
56 specific overexpression of calcineurin (hyp) and wild type controls (Cntl). Data is  
57  
58  
59  
60

1  
2  
3 expressed as absolute copy number of each isoform per ng RNA, presented as  
4  
5 mean  $\pm$  SEM, n=3 for each time point. \*, p<0.05 versus wild type controls, ‡ p<0.05  
6  
7 versus JM-a.  
8  
9

### 10 11 12 **Figure 5 Generation of shRNA knockdown-resistant (kdr) versions of ErbB4**

13  
14 **isoforms. A)** schematic diagram of mutations (red, underlined) introduced into  
15  
16 ErbB4 isoforms to make them insensitive to shRNA knockdown without altering the  
17  
18 amino acid sequence. **B)** the kdr versions of the ErbB4 isoforms were co-expressed  
19  
20 in COS-7 cells with ErbB4 shRNA 1386 (the shRNA targets a 21 bp sequence of  
21  
22 ErbB4 starting at position 1386) or a control shRNA. Western blotting was used to  
23  
24 determine ErbB4 expression.  
25  
26  
27  
28  
29

### 30 31 **Figure 6: Regulation of hypertrophy gene induction by ErbB4 isoforms.**


32  
33 Cardiomyocytes were transfected with 100 ng of ErbB4 shRNA (shErbB4) or Control  
34  
35 shRNA , 300 ng of luciferase reporter construct driven by **A)** MLC-2V, **B)** ANP, or **C)**  
36  
37 cyclin D promoter and 100 ng of empty vector (v) or knockdown resistant versions of  
38  
39 JM-a CYT-1 (a1), JM-a CYT-2 (a2), JM-b CYT-1 (b1) or JM-b CYT-2 (b2) prior to  
40  
41 stimulation with NRG1 (NRG1- $\beta$ 1, 10 nM) for 48 h and determination of luciferase  
42  
43 activity in cell extracts. (n=4-5). **C)** Cells, transfected as above, except with 20 ng, 40  
44  
45 ng, 60 ng, 80 ng or 100 ng of ErbB4 knockdown-resistant constructs were stimulated  
46  
47 with NRG1 (10 nM) for 48 h (n=9). \*0.05 vs. NRG1-stimulated knockdown; ‡ p<0.05  
48  
49 vs. unstimulated knockdown.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Supplementary Information

**Supplementary Figure S1: Knockdown of ErbB2 and ErbB4 using shRNA.**


CHO cells were transfected or not (None) with 500ng of plasmids expressing either ErbB2 (**A**) or ErbB4 (**B**), and 500ng of shRNA targeting ErbB2 (shErbB2, shB2) or ErbB4 (shErbB4, shB4), or non-targeting shRNA control (shControl, shCon) or no shRNA (-). Expression of ErbB2 (**A**) or ErbB4 (**B**) was determined by Western blot with  $\beta$ -actin as a loading control.





### Supplementary Figure S2: Selective knockdown of ErbB receptor expression

with siRNA. CMs were transfected with 20nM siRNA targeting individual ErbB receptors. Expression of ErbB receptors was determined via Western blotting or qPCR 48-96h after transfection. The upper images are representative images of three independent Western blots probing for ErbB2 or ErbB4. The lower graph demonstrates quantification of ErbB2 (left) and ErbB4 (right) expression using Image Studio Lite software (version 3.1). Data shown as mean  $\pm$  SEM (n=3-4) and analysed by two-way ANOVA (\* $p$  < 0.05 vs. siControl).



### Supplementary Figure S3: Expression profile of ErbB4 isoforms during

**embryogenesis and early development.** RNA was isolated from mouse hearts at embryonic day (E) E10.5, E18.5, postnatal (P) day P1 and P28 and the expression of the ErbB4 isoforms JM-a (upper left), JM-b (upper middle), CYT-1 (lower left) and CYT-2 (lower right) quantified. Ratios of JM-a/JM-b and CYT1/CYT2 (right) were also determined. Data is expressed as absolute copy number of each isoform per ng RNA, presented as mean  $\pm$  SEM,  $n=3$  for each time point. (\* $p < 0.05$  vs. E10.5)




Figure 1

Figure 1 Wang et al.

254x190mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2

Figure 2 Wang et al.

254x190mm (96 x 96 DPI)




Figure 3

Wang et al. Fig. 3

254x190mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4

Wang et al. Fig. 4

254x190mm (96 x 96 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 6

Wang et al. Fig. 6

254x190mm (96 x 96 DPI)